Customized Pharmaceutics: Innovations for Diverse Populations

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 3272

Special Issue Editors


E-Mail Website
Guest Editor
Departamento de Produção de Matéria-Prima, Unviersidade Federal do Rio Grande do Sul, Porto Alegre 90610-000, RS, Brazil
Interests: nanotechnology; pharmaceutical technology, skin; cosmetics; pediatric products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Departamento de Produção de Matéria-Prima, Unviersidade Federal do Rio Grande do Sul, Porto Alegre 90610-000, Brazil
Interests: nanotechnology; pharmaceutical technology, skin; cosmetics; dermatological products; topical products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of pharmaceutics continually evolves to meet the unique needs of diverse populations, including pediatrics, geriatrics, and veterinary medicine. The demand for customized pharmaceutical solutions tailored to specific requirements is continually rising. From developing age-appropriate formulations for children to addressing the complexities of medication management in the elderly, and catering to the distinct physiological characteristics of animals, the pursuit of innovation in customized pharmaceutics remains a challenge. Advances in the field comprise, for example, nanotechnology, 3D printing and taste-masking technologies for enhanced palatability. This Special Issue aims to explore the latest developments in this dynamic field, emphasizing the importance of addressing the diverse needs of pediatric, geriatric, and veterinary patients through innovative pharmaceutical approaches.

Dr. Irene Clemes Külkamp-Guerreiro
Dr. Renata Vidor Contri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • 3D printing
  • quality by design
  • patient-centric approaches
  • customized pharmaceuticals
  • pediatrics
  • geriatrics
  • veterinary medicine
  • age-appropriate formulations
  • taste masking

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2361 KiB  
Article
Net Promoter Score Model for Evaluating Paediatric Medicine Acceptability: Validation and Feasibility Study
by Okhee Yoo, Demi Stanford, Britta S. von Ungern-Sternberg and Lee Yong Lim
Pharmaceutics 2024, 16(12), 1513; https://doi.org/10.3390/pharmaceutics16121513 - 25 Nov 2024
Viewed by 859
Abstract
Background/Objectives: Medicine acceptability is crucial for paediatric drug development, yet its assessment remains challenging due to the multifaceted nature of sensory attributes like taste, smell, and mouthfeel. Traditional methods of acceptability evaluation often involve complex questionnaires and lack standardisation, leading to difficulties [...] Read more.
Background/Objectives: Medicine acceptability is crucial for paediatric drug development, yet its assessment remains challenging due to the multifaceted nature of sensory attributes like taste, smell, and mouthfeel. Traditional methods of acceptability evaluation often involve complex questionnaires and lack standardisation, leading to difficulties in a comparative analysis across studies. This study aimed to develop a simplified, standardised approach for assessing medicine acceptability introducing the Net Promoter Score (NPS) framework to derive a Medicine Acceptability Score (MAS). Methods: A retrospective analysis was conducted using taste assessment data from nine paediatric formulations across four studies. The MAS was calculated by identifying an optimal range for categorising participant responses, which encapsulated diverse sensory attributes into a single metric. Validation was performed across various age groups and different formulations to test the reliability and discriminatory power of MAS. Results: The MAS effectively discriminated between acceptable and unacceptable formulations, providing a practical tool for formulation development. Conclusions: The MAS offers a novel, standardised metric for evaluating paediatric medicine acceptability, addressing key limitations of traditional methods. Future studies are recommended to refine the MAS model through the establishment of benchmark scores for chronic and acute medications, thereby standardising acceptability assessment of medicines across the pharmaceutical industry. Full article
(This article belongs to the Special Issue Customized Pharmaceutics: Innovations for Diverse Populations)
Show Figures

Figure 1

Review

Jump to: Research

44 pages, 3282 KiB  
Review
The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals
by Jurga Bernatoniene, Jolita Stabrauskiene, Jurga Andreja Kazlauskaite, Urte Bernatonyte and Dalia Marija Kopustinskiene
Pharmaceutics 2025, 17(3), 390; https://doi.org/10.3390/pharmaceutics17030390 - 19 Mar 2025
Cited by 2 | Viewed by 1835
Abstract
Three-dimensional printing technology is transforming pharmaceutical manufacturing by shifting from conventional mass production to additive manufacturing, with a strong emphasis on personalized medicine. The integration of bioinks and AI-driven optimization is further enhancing this innovation, enabling drug production with precise dosages, tailored drug-release [...] Read more.
Three-dimensional printing technology is transforming pharmaceutical manufacturing by shifting from conventional mass production to additive manufacturing, with a strong emphasis on personalized medicine. The integration of bioinks and AI-driven optimization is further enhancing this innovation, enabling drug production with precise dosages, tailored drug-release profiles, and unique multi-drug combinations that respond to individual patient needs. This advancement is significantly impacting healthcare by accelerating drug development, encouraging innovative pharmaceutical designs, and enhancing treatment efficacy. Traditional pharmaceutical manufacturing follows a one-size-fits-all approach, which often fails to meet the specific requirements of patients with unique medical conditions. In contrast, 3D printing, coupled with bioink formulations, allows for on-demand drug production, reducing dependency on large-scale manufacturing and storage. AI-powered design and process optimization further refine dosage forms, printability, and drug release mechanisms, ensuring precision and efficiency in drug manufacturing. These advancements have the potential to lower overall healthcare costs while improving patient adherence to medication regimens. This review explores the potential, challenges, and environmental benefits of 3D pharmaceutical printing, positioning it as a key driver of next-generation personalized medicine. Full article
(This article belongs to the Special Issue Customized Pharmaceutics: Innovations for Diverse Populations)
Show Figures

Figure 1

Back to TopTop